Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9vHPV Vaccine in Adult Males
NCT04199689Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection comparing 9vHPV vaccine with Placebo (2 arms). Primary endpoint: Incidence of HPV 16/18/31/33/45/52/58-related 6-month Persistent Oral Infection. Started Feb 2020; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04199689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199689.